Carina Biotech

Executive Summary

Carina Biotech is an Australian clinical-stage immunotherapy company focused on developing next-generation CAR-T cell therapies for solid cancers. Founded in 2020 and based in Adelaide, the company leverages proprietary homing-signal and manufacturing platforms to create patient-specific adoptive cell treatments designed to infiltrate tumors while minimizing off-target toxicity. Carina's approach addresses key limitations of current CAR-T therapies, particularly poor trafficking into solid tumors and the immunosuppressive tumor microenvironment. The company is currently in Phase 1 clinical development, targeting multiple solid tumor indications. As a private entity with an estimated 50-200 employees, Carina has not disclosed total funding or valuation, but its innovative platform positions it as a potential leader in the solid tumor CAR-T space. The company's progress in early-stage trials will be critical for validating its technology and attracting further investment or partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout at a major oncology conference60% success
• Q4 2026Regulatory clearance for a new clinical trial or IND expansion70% success
• H2 2026Strategic partnership or licensing deal for manufacturing platform50% success